| Literature DB >> 28352126 |
Łukasz Okruszek1, Aleksandra Bala2, Małgorzata Wordecha3, Michał Jarkiewicz4, Adam Wysokiński5, Ewa Szczepocka5, Aleksandra Piejka2, Oliwia Zaborowska2, Marta Szantroch6, Andrzej Rysz6, Andrzej Marchel6.
Abstract
Social cognition deficits are observed both in patients with schizophrenia (SCZ) and in patients with mesial temporal lobe epilepsy (MTLE). This may be due to dysfunction of the amygdala network, which is a common feature of both diseases. In this study, SCZ (n = 48) or MTLE (n = 31) and healthy controls (HC, n = 47) completed assessments of mentalising (Reading Mind in the Eyes Test, RMET) and basic cognitive processing, e.g., working memory, executive functions and psychomotor speed (Trail-Making Test B and Digit Symbol). SCZ were also assessed with the Positive And Negative Syndrome Scale (PANSS). We found that the RMET scores of the two clinical groups were similar (p > 0.05) and lower than in the HCs (SCZ: p < 0.05; MTLE: p < 0.001). In the next step, SCZ were split into two groups with respect to the level of symptoms. Analysis of the RMET scores revealed no differences between the HC (M = 25.7 ± 4.1) and POS-LO (M = 25.3 ± 4.8); both groups outperformed the POS-HI group (M = 21.3 ± 5.2) and the MTLE group (M = 20.8 ± 4.6). No differences were found for the median-split with regard to negative symptoms. In SCZ, the mind-reading deficit appears to be associated with the level of positive symptoms. Both POS-HI and MTLE patients present significant mentalising deficits compared to healthy controls.Entities:
Mesh:
Year: 2017 PMID: 28352126 PMCID: PMC5428695 DOI: 10.1038/s41598-017-00565-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Results of cognitive (number of items coded for Digit Symbol; time in seconds for TMT-B) and mind-reading (number of items classified correctly in RMET) assessment. Error bars are for standard deviations. SCZ – patients with schizophrenia; MTLE – patients with temporal lobe epilepsy; HC – healthy controls.
Basic sociodemographic and clinical characteristics of the subgroups of patients with schizophrenia.
| SCZ POS_HI (n = 24) | SCZ POS_LO (n = 24) | ||
|---|---|---|---|
| Age (years) | 35.5 [10.5] | 36.0 [6.4] | F(3,122) = 2.3 n.s. |
| Gender | 12/12 (50%) | 14/10 (58%) | Χ2 = 1.0 n.s. |
| Education | 12.2 [1.9] | 14.5 [2.6] | F(3,122) = 18.2***HC >SCZ POS_HI; MTLE; SCZ POS_LO >SCZ POS_HI |
| PANSS_POS | 21.0 [3.8] | 9.9 [1.8] | t(46) = 13.0*** |
| PANSS_NEG | 24.4 [8.8] | 18.3 [4.3] | t(46) = 3.1** |
| PANSS_TOT | 85.3 [19.1] | 55.2 [8.7] | t(46) = 5.8*** |
| Treatment | Χ2 = 0.6 n.s. | ||
| Monotherapy with SGA | 12 | 13 | |
| Polytherapy with SGA | 11 | 8 | |
| No medication | 0 | 1 | |
| Mono- or polytherapy with FGA | 1 | 2 |
All of the values are given in an M [SD] format with an exception for gender, where the M/F ratio is given. SCZ POS_HI – patients with a high level of positive symptoms; SCZ POS_LO – patients with a low level of positive symptoms.
Basic sociodemographic and clinical characteristics of the participants of the study.
| SCZ (n = 48) | MTLE (n = 31) | HC (n = 47) | ||
|---|---|---|---|---|
| Age (years) | 35.8 [8.6] | 30.9 [7.7] | 32.3 [9.1] | F(2,125) = 2.3 n.s. |
| Gender | 26/22 (54%) | 14/17 (45%) | 25/22 (53%) | Χ2 = 0.6 n.s. |
| Education | 13.4 [2.5] | 13.0 [2.9] | 15.9 [1.8] | F(2,125) = 19.3*** HC > SCZ, MTLE |
All of the values are given in M [SD] format with the exception of gender, where the M/F ratio is given. SCZ – patients with schizophrenia; MTLE – patients with mesial temporal lobe epilepsy; HC – healthy controls.